Plasma soluble receptor for advanced glycation end-products and risk of colorectal adenoma

International Journal of Molecular Epidemiology and Genetics

Volumn 3, Issue 4, 2012, Pages 294-304

  Jiao, Li ^a,b   Chen, Liang ^a,b   Alsarraj, Abeer ^a   Ramsey, David ^a   Duan, Zhigang ^a   El Serag, Hashem B ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Case control; Colorectal adenoma; Inflammation; NF B; Risk; sRAGE; VEGF

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALPHA2 INTERFERON; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6 RECEPTOR; LYMPHOTOXIN; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; VASCULOTROPIN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER RISK; CASE CONTROL STUDY; COLONOSCOPY; COLORECTAL ADENOMA; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HYPERTENSION; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSPECTIVE STUDY; QUESTIONNAIRE; SMOKING;

EID: 84869857959     PISSN: None     EISSN: 19481756     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Jacobs ET, Ahnen DJ, Ashbeck EL, Baron JA, Greenberg ER, Lance P, Lieberman DA, Keown-Eyssen G, Schatzkin A, Thompson PA, Martinez ME. Association between body mass index and colorectal neoplasia at follow-up colonoscopy: a pooling study. Am J Epidemiol 2009; 169: 657-666.
2. Gunter MJ, Stolzenberg-Solomon R, Cross AJ, Leitzmann MF, Weinstein S, Wood RJ, Virtamo J, Taylor PR, Albanes D, Sinha R. A prospective study of serum C-reactive protein and colorectal cancer risk in men. Cancer Res 2006; 66: 2483-2487.
3. Kim S, Keku TO, Martin C, Galanko J, Woosley JT, Schroeder JC, Satia JA, Halabi S, Sandler RS. Circulating levels of inflammatory cytokines and risk of colorectal adenomas. Cancer Res 2008; 68: 323-328.
4. Sasaki Y, Takeda H, Sato T, Orii T, Nishise S, Nagino K, Iwano D, Yaoita T, Yoshizawa K, Saito H, Tanaka Y, Kawata S. Serum Interleukin-6, insulin, and HOMA-IR in male individuals with colorectal adenoma. Clin Cancer Res 2012; 18: 392-399.
5. Bobe G, Albert PS, Sansbury LB, Lanza E, Schatzkin A, Colburn NH, Cross AJ. Interleukin-6 as a potential indicator for prevention of high-risk adenoma recurrence by dietary flavonols in the polyp prevention trial. Cancer Prev Res (Phila) 2010; 3: 764-775.
6. Logsdon CD, Fuentes MK, Huang EH, Arumugam T. RAGE and RAGE ligands in cancer. Curr Mol Med 2007; 7: 777-789.
7. Yan SF, Ramasamy R, Schmidt AM. Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response. J Mol Med 2009; 87: 235-247.
8. Heijmans J, Buller NV, Hoff E, Dihal AA, van der PT, van Zoelen MA, Bierhaus A, Biemond I, Hardwick JC, Hommes DW, Muncan V, van den Brink GR. Rage signalling promotes intestinal tumourigenesis. Oncogene 2012; doi: 10.1038/onc.2012.119
9. Zen K, Chen CX, Chen YT, Wilton R, Liu Y. Receptor for advanced glycation endproducts mediates neutrophil migration across intestinal epithelium. J Immunol 2007; 178: 2483-2490.
10. Kuniyasu H, Chihara Y, Takahashi T. Co-expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer. Oncol Rep 2003; 10: 445-448.
11. Jiao L, Taylor PR, Weinstein SJ, Graubard BI, Virtamo J, Albanes D, Stolzenberg-Solomon RZ. Advanced glycation end products, soluble receptor for advanced glycation end products, and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2011; 20: 1430-1438.
12. Kalousova M, Hodkova M, Kazderova M, Fialova J, Tesar V, Dusilova-Sulkova S, Zima T. Soluble receptor for advanced glycation end products in patients with decreased renal function. Am J Kidney Dis 2006; 47: 406-411.
13. Sasahira T, Akama Y, Fujii K, Kuniyasu H. Expression of receptor for advanced glycation end products and HMGB1/amphoterin in colorectal adenomas. Virchows Arch 2005; 446: 411-415.
14. van B Jr, Buurman WA, Griffioen AW. Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis 2008; 11: 91-99.
15. Cammarota R, Bertolini V, Pennesi G, Bucci EO, Gottardi O, Garlanda C, Laghi L, Barberis MC, Sessa F, Noonan DM, Albini A. The tumor microenvironment of colorectal cancer: stromal TLR-4 expression as a potential prognostic marker. J Transl Med 2010; 8: 112-127.
16. Nihon-Yanagi Y, Terai K, Murano T, Matsumoto T, Okazumi S. Tissue expression of Toll-like receptors 2 and 4 in sporadic human colorectal cancer. Cancer Immunol Immunother 2012; 61: 71-77.
17. Falcone C, Buzzi MP, Bozzini S, Boiocchi C, D'Angelo A, Schirinzi S, Esposito C, Torreggiani M, Choi J, Ochan KM, Mancia G. Microalbuminuria and sRAGE in high-risk hypertensive patients treated with nifedipine/telmisartan combination treatment: a substudy of TALENT. Mediators Inflamm 2012; 2012: 874149-874154.
18. Liang H, Zhong Y, Zhou S, Peng L. Knockdown of RAGE expression inhibits colorectal cancer cell invasion and suppresses angiogenesis in vitro and in vivo. Cancer Lett 2011; 313: 91-98.
19. Alferez D, Wilkinson RW, Watkins J, Poulsom R, Mandir N, Wedge SR, Pyrah IT, Smith NR, Jackson L, Ryan AJ, Goodlad RA. Dual inhibition of VEGFR and EGFR signaling reduces the incidence and size of intestinal adenomas in Apc(Min/+) mice. Mol Cancer Ther 2008; 7: 590-598.
20. Wong MP, Cheung N, Yuen ST, Leung SY, Chung LP. Vascular endothelial growth factor is upregulated in the early pre-malignant stage of colorectal tumour progression. Int J Cancer 1999; 81: 845-850.
21. Kazama S, Kitayama J, Watanabe T, Nagawa H. Expression pattern of vascular endothelial growth factor-C in human colorectal normal mucosa and neoplastic mucosa. Hepatogastroenterology 2004; 51: 391-395.
22. Hanrahan V, Currie MJ, Gunningham SP, Morrin HR, Scott PA, Robinson BA, Fox SB. The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression. J Pathol 2003; 200: 183-194.
23. Abdou AG, Aiad H, Asaad N, bd El-Wahed M, Serag El-Dien M. Immunohistochemical evaluation of vascular endothelial growth factor (VEGF) in colorectal carcinoma. J Egypt Natl Canc Inst 2006; 18: 311-322.
24. Fujisaki K, Mitsuyama K, Toyonaga A, Matsuo K, Tanikawa K. Circulating vascular endothelial growth factor in patients with colorectal cancer. Am J Gastroenterol 1998; 93: 249-252.
25. Koretz K, Schlag P, Moller P. Expression of epidermal growth factor receptor in normal colorectal mucosa, adenoma, and carcinoma. Virchows Arch A Pathol Anat Histopathol 1990; 416: 343-349.
26. Rothbauer E, Mann K, Wiebecke B, Borlinghaus P, Lamerz R, Pratschke E, Kramling HJ, Pfeiffer A. Epidermal growth factor receptors and epidermal growth factor-like activity in colorectal mucosa, adenomas and carcinomas. Klin Wochenschr 1989; 67: 518-523.
27. Malecka-Panas E, Kordek R, Biernat W, Tureaud J, Liberski PP, Majumdar AP. Differential activation of total and EGF receptor (EGF-R) tyrosine kinase (tyr-k) in the rectal mucosa in patients with adenomatous polyps, ulcerative colitis and colon cancer. Hepatogastroenterology 1997; 44: 435-440.
28. Tanaka S, Tatsuguchi A, Futagami S, Gudis K, Wada K, Seo T, Mitsui K, Yonezawa M, Nagata K, Fujimori S, Tsukui T, Kishida T, Sakamoto C. Monocyte chemoattractant protein 1 and mac rophage cyclooxygenase 2 expression in colonic adenoma. Gut 2006; 55: 54-61.
29. Kim S, Keku TO, Martin C, Galanko J, Woosley JT, Schroeder JC, Satia JA, Halabi S, Sandler RS. Circulating levels of inflammatory cytokines and risk of colorectal adenomas. Cancer Res 2008; 68: 323-328.
30. Bobe G, Murphy G, Albert PS, Sansbury LB, Lanza E, Schatzkin A, Colburn NH, Cross AJ. Serum cytokine concentrations, flavonol intake and colorectal adenoma recurrence in the Polyp Prevention Trial. Br J Cancer 2010; 103: 1453-1461.
31. Hopkins MH, Fedirko V, Jones DP, Terry PD, Bostick RM. Antioxidant micronutrients and biomarkers of oxidative stress and inflammation in colorectal adenoma patients: results from a randomized, controlled clinical trial. Cancer Epidemiol Biomarkers Prev 2010; 19: 850-858.
32. Hopkins MH, Owen J, Ahearn T, Fedirko V, Flanders WD, Jones DP, Bostick RM. Effects of supplemental vitamin D and calcium on biomarkers of inflammation in colorectal adenoma patients: a randomized, controlled clinical trial. Cancer Prev Res (Phila) 2011; 4: 1645-1654.